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IGFBPL1 Regulates Axon Growth 
through IGF-1-mediated Signaling 
Cascades
Chenying Guo1, Kin-Sang Cho1, Yingqian Li1, Kissauo Tchedre1, Christian Antolik1,  
Jie Ma1, Justin Chew1,2, Tor Paaske Utheim1,3, Xizhong A. Huang1,4, Honghua Yu1,  
Muhammad Taimur A. Malik1, Nada Anzak1,5 & Dong Feng Chen1,6
Activation of axonal growth program is a critical step in successful optic nerve regeneration following 
injury. Yet the molecular mechanisms that orchestrate this developmental transition are not fully 
understood. Here we identified a novel regulator, insulin-like growth factor binding protein-like 1 
(IGFBPL1), for the growth of retinal ganglion cell (RGC) axons. Expression of IGFBPL1 correlates with 
RGC axon growth in development, and acute knockdown of IGFBPL1 with shRNA or IGFBPL1 knockout 
in vivo impaired RGC axon growth. In contrast, administration of IGFBPL1 promoted axon growth. 
Moreover, IGFBPL1 bound to insulin-like growth factor 1 (IGF-1) and subsequently induced calcium 
signaling and mammalian target of rapamycin (mTOR) phosphorylation to stimulate axon elongation. 
Blockage of IGF-1 signaling abolished IGFBPL1-mediated axon growth, and vice versa, IGF-1 
required the presence of IGFBPL1 to promote RGC axon growth. These data reveal a novel element 
in the control of RGC axon growth and suggest an unknown signaling loop in the regulation of the 
pleiotropic functions of IGF-1. They suggest new therapeutic target for promoting optic nerve and axon 
regeneration and repair of the central nervous system.
The exuberant growth of axons in the mammalian central nervous system (CNS) becomes markedly reduced 
as neurons mature. This is in part a result of the developmental shutdown of the axon growth program which 
contributes critically to the failure of CNS regeneration and repair after injury1–4. Retinal ganglion cells (RGCs), 
which have long served as a standard model of CNS neurons, switch off the intrinsic axon growth program during 
the prenatal period in mice5–7. Upon differentiation, developing RGCs must receive accurate and timely stimu-
lation to initiate the intrinsic axon growth program for successful development of the optic nerve. One potential 
mechanism is governed through secretory factors that, when bound to neurons, switch on intracellular axon 
growth cascades, while their absence turns off the axon growth signals and leads to loss of nerve regenerative 
capacity. These factors may represent important targets for therapeutic interventions to promote regeneration 
after CNS injury. To date, the molecular signals that orchestrate the transition of RGC axon growth cascades have 
not been fully understood.
Studies have suggested that IGF-1 (insulin-like growth factor-1) is required for the growth of CNS axons. The 
question remains as how IGF-1 activates the axon growth machinery in the developing, but not adult, neurons of 
the CNS. Intriguingly, IGF-1 mediates not only axon growth, but multiple other biological processes of developing 
neurons, including proliferation, survival, and synaptogenesis. To date, at least 7 IGF binding proteins (IGFBPs) 
and an IGFBP like protein 1 (IGFBPL1) are identified. We hypothesized that IGF-1 requires IGFBP, which may 
be expressed during certain period in development, to selectively enable the activation of IGF-1-induced plei-
otropic signaling cascades. In the present study, we showed that IGFBPL1 is a critical co-factor of IGF-1 for its 
activation of axon growth cascades. Acute knockdown of IGFBPL1 with shRNA nullifies IGF-1-induced axon 
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growth activities in developing RGCs. In contrast, administration of IGFBPL1 stimulated RGC axon elonga-
tion. IGFBPL1 activates the axonal growth machinery by binding with IGF-1 to enable intracellular Ca2+ eleva-
tion essential for axon extension. Finding of the function of IGFBPL1 in IGF-1-mediated axon growth function 
unveils a new regulatory element in its pleiotropic activities. IGFBPL1, as a secretory factor that directly regulates 
axonal growth, may present a possibility for pharmacological manipulation to promote axon regeneration and 
reverse vision loss after injury in human patients.
Results
Developmental loss of IGFBPL1 expression correlates with the cessation of RGC axon growth. 
Mouse RGC axons switch off exuberant growth between embryonic day 16 (E16) and birth (P0)6,8 presents a 
unique tractable model for identification of candidate regulators of axonal growth by comparing gene expression 
profiles. Through analysis of cDNA microarray data obtained from E16 and P0 retinas, a novel secretory protein 
IGFBPL1 emerged as a candidate molecule whose levels of expression correlated with RGC axon growth capac-
ity. This result was confirmed by quantitative RT-PCR (qPCR) that examined RNA levels in the retinas of E16, 
P0, and adult mice (Fig. 1A). β-III-tubulin, as shown by our lab and others, is a marker of RGCs in the GCL of 
the mouse retina9,10. Double-immunolabeling of IGFBPL1 and a primary antibody against β-III-tubulin (Tuj1; 
Fig. 1B and Supplementary Fig. 1) revealed that IGFBPL1 was highly enriched in the ganglion cell layer (GCL) of 
E16 retinas. Its expression dropped sharply at P0 and became non-detectable after P10 to adulthood (Fig. 1A,B). 
During development, exuberant growth of RGC axons is largely reduced by P0, while a sub-cohort of late-born 
RGCs is reported to continue extending axons up to P6-711–13. The spatiotemporal expression of IGFBPL1 thus 
correlates precisely with the growth status of RGC axons, raising the possibility that IGFBPL1 participates in the 
regulation of RGC axonal growth.
IGFBPL1 mediates RGC axon growth in vitro. To explore the role of IGFBPL1 in RGC axonal growth, 
we utilized shRNA silencing to acutely knockdown the expression of IGFBPL1 in a standard model of purified 
RGC cultures. Primary RGCs isolated from newborn (P0) mouse pups were infected with lentiviral particles 
carrying IGFBPL1 shRNA or scrambled shRNA tagged with green fluorescence protein (GFP). After 3 days of 
incubation, RGCs infected by IGFBPL1 shRNA, but not scrambled shRNA, exhibited a complete knockdown of 
Figure 1. Developmental downregulation of IGFBPL1 in the retina. (A) Quantification of IGFBPL1 mRNA 
levels with qPCR (normalized to the E16 level) in the developing mouse retina showing drastic downregulation 
of IGFBPL1 expression at P0 (n = 5 mice/time point). ***P < 0.001, as compared to the E16 group by two-tailed 
student t-test. Error bars indicate standard error of mean (SEM). (B) Epifluorescence photomicrographs of 
retinal sections from E16, P0, P10 and adult mice (2 months) double-immunolabeled with primary antibodies 
against IGFBPL1 (red) and RGC specific marker Tuj1 (green); retinal sections were counterstained with a 
nuclear marker DAPI (blue). Note the bright labeling of IGFBPL1 in E16 ganglion cell layer (GCL) that was 
down-regulated after birth and became extinct after P10. GCL, ganglion cell layer. Scale bars: 50 µm.
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IGFBPL1 mRNA and protein expression as revealed by qPCR and Western blot (Fig. 2A–C and Supplementary 
Fig. 2); the expression of other genes, e.g. IGF-1 and p53, was not affected. Accompanied with the knockdown 
of IGFBPL1, we noted an over 30-fold reduction in average axon length (Fig. 2D) and a 7-fold reduction in the 
number of RGCs bearing axons (Fig. 2E), but only a moderate reduction (~30%) of RGC survival, compared to 
cultures treated with scrambled shRNA (Fig. 2F). Notably, surviving RGCs in IGFBPL1 shRNA treated cultures 
did not grow neurites, indicating their impaired ability to grow axons. To test if IGFBPL1 can stimulate RGC 
axon outgrowth in culture, recombinant mouse IGFBPL1 protein was added to the cultured RGCs purified from 
P0 mouse pups (Fig. 2G). After 3 days of incubation, addition of IGFBPL1 significantly enhanced RGC axonal 
Figure 2. Role of IGFBPL1 for RGC axonal outgrowth in vitro. (A) Representative photomicrographs of 
cultured RGCs infected with lentiviral vectors carrying scrambled shRNA or IGFBPL1 shRNA tagged by a GFP 
reporter gene. Scale bar: 20 um. (B) qPCR results of IGFBPL1, IGF-1 and p53 mRNA levels in P0 RGC cultures 
infected by lentiviruses carrying either scrambled or IGFBPL1 shRNAs. mRNA levels were normalized to that 
of the untreated RGCs. (C) Representative images of Western blot analysis of IGFBPL1 (upper) quantification 
in P0 RGC cultures infected by scrambled or IGFBPL1 shRNA; β-actin (lower) was used as a loading control. 
The original images are shown in Supplementary Fig. 2. (D) Quantification of axon length in P0 RGC cultures 
infected by lentiviruses carrying either scrambled or IGFBPL1 shRNAs. (E,F) Percentage of cells bearing 
axons (E) and cell survival (F) in cultures infected by lentiviral vectors carrying scrambled shRNA or IGFBPL1 
shRNA. (G) Representative epifluorescence photomicrographs of cultured P0 RGCs in the absence (a) or 
presence (b) of IGFBPL1 (400 ng/ml). Cells were immunolabeled with Tuj1 (red). Scale bar: 20 um. (H–J) 
Quantification of axon length (H), percentage of cells bearing axons (I) and percentage of surviving cells (J) 
in cultured P0 RGCs treated with various concentrations of IGFBPL1, n = 6 cultures/group. ***P < 0.001, 
**P < 0.01, as compared to the control group by two-tailed student t-test. Error bars indicate standard error of 
mean (SEM).
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outgrowth (Fig. 2H,I). At the optimal concentration (400 ng/ml), administration of IGFBPL1 induced a 3-fold 
increase in axon length and 2-fold increase in the number of RGCs bearing axons; whereas, addition of IGFBPL1 
did not significantly increase RGC survival (Fig. 2I). Thus, IGFBPL1 regulates RGC axonal growth without sig-
nificantly affecting cell survival.
To determine if the axon growth promoting effect of IGFBPL1 is limited to RGCs, we knocked down IGFBPL1 
in PC12 cells and mouse hippocampus neurons. Consistently, we observed reduced neurite length without 
significant change in cell survival in both PC12 (Supplementary Fig. 3A,B) and hippocampal neuron cultures 
(Supplementary Fig. 3C,D). Addition of IGFBPL1, in contrast, led to significantly increased neurite outgrowth 
in PC12 cell (Supplementary Fig. 4A,B) and hippocampal neuron cultures (Supplementary Fig. 4C,D). Together, 
these data indicate that IGFBPL1 is generally involved in the regulation of neuron axon growth.
IGFBPL1 deficiency impaired RGC axon growth in vivo. To investigate if IGFBPL1 is required for RGC 
axonal growth in vivo during development, we generated Igfbpl1 null mutant (Igfbpl1−/−) mice. Quantification 
with qPCR confirmed the absence of IGFBPL1 mRNA in homozygous knockout (Igfbpl1−/−) mice (Fig. 3A). 
Igfbpl1−/− mice were viable and fertile without apparent growth defects or phenotypes. The retinas of newborn 
Igfbpl1+/− and Igfbpl1−/− mice displayed normal laminar structure, and immunohistochemistry. Results of qPCR 
that examined the expression of various retinal cell markers revealed no significant defects associated with pho-
toreceptor and interneuron gene expression (not shown). In agreement with the specific localization of IGFBPL1 
in RGCs, new born Igfbpl1−/− mice exhibited a largely reduced number of axons (~40%) in the optic nerve com-
pared to wild-type (WT) littermates (Fig. 3B,C), while they showed approximately 20% reduction in number of 
RGCs as compared to the WT littermates (Fig. 3D,E).
To verify that impaired axon growth in Igfbpl1−/− mice is a direct consequence of IGFBPL1 deficiency, we iso-
lated RGCs from newborn (P0) Igfbpl1+/− and Igfbpl1−/− mice. RGCs taken from P0 Igfbpl1+/− and Igfbpl1−/− mouse 
pups exhibited a 50% reduction in axon length in culture compared to WT littermates (Fig. 3F,G); whereas, the sur-
vival of RGCs of Igfbpl1−/− mice was reduced by only ~15% compared to WT mice (Fig. 3H). Addition of IGFBPL1 
protein to RGCs of Igfbpl1−/− mice in culture completely rescued the axonal growth and survival defects (Fig. 3G,H), 
suggesting that these growth defects were a result of IGFBPL1 deficiency rather than developmental defects of other 
cellular cascades. The data supports that IGFBPL1 plays an important role in mediating RGC axon growth during 
development in vivo. The relatively milder impact of gene deletion of IGFBPL1 on RGC axon growth than the acute 
knockdown of IGFBPL1 with shRNA suggests possible functional redundancy among IGFBPs.
IGFBPL1 regulates axon growth through binding to IGF-1. Because IGFBPL1 shares an IGF-1 bind-
ing domain with all IGFBPs, we asked if IGFBPL1 binds IGF-1 in axon growth regulation. We examined the direct 
physical interaction of IGFBPL1 and IGF-1 using purified recombinant proteins. Bacterially produced IGF-1 was 
co-immunoprecipitated (co-IPed) with recombinant IGFBPL1, which was purified from a mouse myeloma cell 
line. Notably, recombinant IGF-1 bound to IGFBPL1 ex vivo (Fig. 4A), suggesting that IGF-1 can directly bind 
with IGFBPL1. To test if IGFBPL1 directly interacts with IGF-1 in vivo under physiological conditions, retinal 
lysates of newborn mice were co-IPed using IGFBPL1 or IGF-1 antibodies. IGFBPL1 was precipitated from the 
retinal lysates with an anti-IGF-1 antibody, and reciprocally, IGF-1 was detected in the co-IPed product pulled 
down by anti-IGFBPL1 antibody (Fig. 4B). These results indicate the physical interactions of IGFBPL1 and IGF-1 
in vivo at the physiologically relevant protein levels.
We proposed that the interaction between IGF-1 and IGFBPL1 enables RGC axonal growth signaling. To 
test this, NBI-31772 (NBI), a non-peptide ligand that displaces IGF-1 from all currently known IGF-1 binding 
proteins14, was administered to P0 RGC cultures. NBI completely abolished the axon growth-promoting effect of 
IGFBPL1 (Fig. 4C,D). Moreover, H1356, an IGF-1 analog that competitively blocks the binding of IGF-1 with its 
receptor IGF-1R, also abolished the axonal growth promoting activity of IGFBPL1 (Fig. 4C,D). Thus, IGFBPL1 
requires physical interaction with IGF-1 and activation of IGF-1R to promote RGC axon growth.
IGFBPL1 is a co-factor for IGF-1 in the control of axonal growth during development. We pro-
posed that if presence of both IGFBPL1 and IGF-1 are needed for stimulating RGC axon growth, IGF-1 and 
IGF-1R should co-exist with IGFBPL1 in the developing retina when RGCs undergo axon elongation. Results of 
immunohistochemistry and Western blot confirmed that IGF-1 was highly enriched in the ganglion cell layer of 
the E16 retina, and its level of expression persisted in P0 RGCs but was largely diminished after P10 (Fig. 5A,B). 
This pattern of IGF-1 expression parallels that of IGF-1R in the retina (Fig. 5C) and is in agreement with the 
reported expression profile of IGF-115. Thus, IGF-1, IGF-1R and IGFBPL1 are concurrently expressed in the per-
inatal retina when RGCs exuberantly grow axons. Down-regulation of IGFBPL1, and to a less extent for IGF-1 or 
IGF-1R, correlates with the cessation of RGC axon elongation in development.
To further investigate if IGFBPL1 functions conjointly with IGF-1 to induce axonal growth, we examined 
RGCs isolated from P10 (rather than P0) mouse pups, when the retina produces minimal amounts of endogenous 
IGF-1 (Fig. 5A,B) and IGFBPL1 (Fig. 1B). As expected, P10 RGCs exhibited minimal axonal growth when was 
treated with a vehicle control. Addition of IGF-1 or IGFBPL1 alone, at increasing doses up to 750 ng/ml, to P10 
RGC cultures did not significantly promote axon growth when compared with the control group (Fig. 6A–E). In 
contrast, co-administration of IGF-1 and IGFBPL1, even at low concentrations (e.g., 75 ng/ml), induced signifi-
cant axon growth through increased axon length and numbers without improvement of cell survival (Fig. 6A–E). 
This result strongly supports that IGFBPL1 is a co-factor of IGF-1 for activating the axon growth signaling.
IGFBPL1 enables IGF-1-induced Ca2+ signaling to promote axonal growth. Elevation of intra-
cellular calcium ([Ca2+]i) is an essential component of the signaling cascades required for the initiation of 
RGC axon growth8. We next examined the changes of [Ca2+]i induced by IGFBPL1 and/or IGF-1 in P10 RGC 
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cultures. Treatment with either IGFBPL1 or IGF-1 alone did not induce significant changes in [Ca2+]i when 
compared to vehicle treated cultures (Fig. 6F,G), corresponding to their inability to stimulate axonal growth in 
P10 RGCs. In contrast, co-application of IGFBPL1 and IGF-1 induced robust elevation of [Ca2+]i over the con-
trol group (Fig. 6F,G). To determine if this elevation of [Ca2+]i was responsible for the axon growth-promoting 
Figure 3. Impaired RGC axon development in Igfbpl1−/− mice. (A) Quantification of IGFBPL1 mRNA levels in 
WT, Igfbpl+/−, and Igfbpl1−/− mouse retinas with qPCR (n = 5 mice/group). (B) Representative images of RGC 
axon morphology in optic nerve cross sections and retinal laminar structure in P0 WT and Igfbpl1−/− mice. 
Optic nerve sections were stained by paraphenylene diamine (PPD) to reveal myelinated axons (Scale bar: 
5 µm). Retinal sections were immunolabeled with primary antibody against RGC specific marker Tuj1 (red) 
and counter-stained by a nuclear marker DAPI. No apparent differences in retinal laminar structure or cell 
densities were noted in WT and igfbpl1−/− mice. Scale bar: 50 µm. (C) Axon counts in optic nerve sections of P0 
WT, Igfbpl1+/− and Igfbpl1−/− mice (n > 5). (D,E) Representative images (D) and counts (E) of RGCs in Tuj1-
immunolabeled retinal whole-mounts from adult WT and Igfbpl1−/− mice. Scale bar: 50 µm. (F) Representative 
epifluorescence photomicrographs of RGCs from littermate P0 WT and Igfbpl1−/− (KO) mouse pups cultured in 
the absence (middle panel) or presence (bottom panel) of IGFBPL1 protein and immunolabeled with Tuj1 (red). 
Addition of IGFBPL1 (200 ng/ml) rescued the neurite growth defect of Igfbpl1−/− (KO) RGCs. Scale bar: 20 µm. 
(G,H). Quantification of RGC axon length (G) and cell survival (H) (n = 5/group). ***P < 0.001, **P < 0.01, 
*P < 0.05, as compared to the WT group by two-tailed student t-test. Error bars indicate standard error of mean 
(SEM).
www.nature.com/scientificreports/
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Figure 4. Function of IGF-1/IGF-1R signaling for IGFBPL1-mediated growth. (A) Co-IP of recombinant 
IGFBPL1 and IGF-1 proteins ex vivo. Anti-IGFBPL1 detected the presence of IGF-1 in the co-IP product and 
vice versa, anti-IGF-1 detected the presence of IGFBPL1 in the protein complex. (B) Co-IP detected IGFBPL1 
(upper panel) and IGF-1 (lower panel) in protein complexes pulled down with primary antibodies against 
IGFBPL1 (middle) or IGF-1 (right). Left lane represents control co-IP result using a control rabbit IgG antibody. 
(C) Representative photomicrographs of cultured P0 RGCs treated with IGF-1 and/or IGFBPL1 in the absence or 
presence of NBI-31772 (NBI; 20 μM) or H1356 (40 μg/ml). Cells were immunolabeled with Tuj1. Scale bar: 20 μm. 
(D) Quantification of axon length in cultured RGCs (n = 5 cultures/group). Note that application of NBI-31772 or 
H1356 completely blocked either IGF-1- or IGFBPL1-induced axonal outgrowth. ***P < 0.001 as compared to the 
control (PBS) group by two-tailed student t-test. Error bars indicate standard error of mean (SEM).
www.nature.com/scientificreports/
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activities, we blocked [Ca2+]i change with Ca2+ chelators, EGTA (ethylene glycol-bis(β-aminoethyl 
ether)-N,N,N′,N′-tetraacetic acid)16,17 or L-type Ca2+ channel antagonist Nifedipine18,19. Administration of 
EGTA or Nifedipine blocked the axon growth-promoting effects induced by co-application of IGFBPL1 and 
IGF-1 (Fig. 7A,C) without affecting cell survival (Fig. 7B). In contrast, administration of Ca2+ channel agonist 
FPL64176 (FPL)—a potent L-type Ca2+ channel activator20,21—to P10 RGC cultures stimulated robust axonal 
outgrowth similar to what was seen in cultures receiving IGFBPL1 and IGF-1 co-treatment (Fig. 7D–F). FPL 
induced a larger than 2-fold increase in axon length over that of the control group. Moreover, addition of FPL 
to RGC cultures receiving IGFBPL1 and IGF-1 co-treatment did not further enhance their axon growth activity 
(Fig. 7D), suggesting that IGF/IGFBPL1 and FPL work through a common mechanism. Thus, the presence of 
IGFBPL1 enables IGF-1 to activate [Ca2+]i signaling and the intracellular events that lead to axonal growth.
As Phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) are indicators of axon growth 
capacity and important downstream signals of RGC axon growth cascades22, we examined if co-application 
of IGFBPL1 and IGF-1 or elevation of [Ca2+]i activates these signals. Western blot analysis showed that nei-
ther IGF-1 nor IGFBPL1 alone induced PI3K phosphorylation in P10 RGCs when compared to vehicle-treated 
controls (Fig. 8A–D). In contrast, co-administration of IGF-1 and IGFBPL1 induced a 6-fold increase in PI3K 
phosphorylation and a 3-fold increase of mTOR phosphorylation compared to the control group (Fig. 8A–D, 
Supplementary Fig. 5). Phosphorylation of PI3K and mTOR induced by IGFBPL1 and IGF-1 co-administration 
was completely blocked by Ca2+ chelator BAPTA (1,2-bis(o-amino phenoxy)ethane-N,N,N′,N′-tetraacetic acid). 
Administration of L-type Ca2+ channel activator FPL, in contrast, resulted in robust PI3K and mTOR activa-
tion, similar to that seen in cultures receiving IGFBPL1 and IGF-1 co-treatment (Fig. 8E,F). Together, our data 
establishes that IGFBPL1 functions as a co-factor of IGF-1 to enable axonal growth via signaling intracellular 
Ca2+-mediated events and activating PI3K and mTOR.
Discussion
The present study has identified a novel regulator and IGF-1 co-factor, IGFBPL1, in the mediation of RGC axon 
growth in vitro and in vivo. IGFBPL1 deficiency impaired axon growth, while administration of IGFBPL1 pro-
moted RGC axonal growth in the presence of IGF-1. We demonstrate that presence of IGFBPL1 enables IGF-1 to 
activate intracellular Ca2+ signaling and PI3K and mTOR pathways and stimulate axon growth. The study unveils 
a new regulatory element in the pleiotropic functions of IGF-1.
Figure 5. Expression of IGF-1 and IGF-1R in the developing retina. (A) Epifluorescence photomicrographs 
of retinal sections taken from E16, P0, P10 and adult mice double-immunolabeled with primary antibodies 
against IGF-1 (red; left panel) and Tuj1 (green; middle panel) and counterstained with nuclear marker DAPI 
(blue). GCL, ganglion cell layer. Scale bars: 50 µm. (B,C) Western blot quantification of IGF-1 (B) and IGF-1R 
(C) expression in retinal lysates taken from E16, P0, P10 and adult mice. Western blot quantifications were 
normalized to GAPDH and reported as relative intensity compared to GAPDH in the bar charts.
www.nature.com/scientificreports/
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During neural development, IGF-1 regulates many, and sometimes dichotomous, aspects of intracellular sig-
nals that support neural survival, differentiation, proliferation, axon growth, and synaptogenesis23. It is evident 
that IGF-1 regulates the initiation of axon growth and specification during development24,25; whereas, it promotes 
only neuronal survival without stimulating axon growth or regeneration in the adult CNS24,26–28. The molecular 
mechanisms underlying the shift of the pleiotropic activities of IGF-1 at various neuron developmental stages 
are unknown. Our study suggests that IGFBPL1, which is transiently expressed during the period of exuberant 
axon growth in development, is an essential co-factor of IGF-1 to enable the axon growth signaling. Restrained 
IGFBPL1 expression during distinct stages of RGC development thus may set the timing for RGC axon elonga-
tion. Up to date, little is reported regarding the transcriptional regulation of IGFBPL1 expression. There is much 
to be discovered about the functional roles for IGFBPL1 and to elucidate if IGFBPL1 also acts independent of 
IGF-1 to drive other cellular functions during development and response to neural injury or stress. In any case, 
these studies define a previously unknown signaling loop in IGF-1 function and reveal a novel mechanism that 
switches off the axonal growth activity of IGF-1.
Our results showed that IGFBPL1 functions through interacting with IGF-1 to enable intracellular Ca2+ sig-
naling and initiate the axon growth program, such as the phosphorylation of PI3K and mTOR. IGF-1 mediates 
Ca2+ signaling pathways via activation of voltage-dependent Ca2+ channels and Akt phosphorylation29,30. Ca2+ 
as a second messenger plays pivotal roles in a variety of cellular processes in neurons, ranging from gene expres-
sion, neurite growth, synaptogenesis, to neurotransmitter release31. Excessive intracellular Ca2+ can also signal 
biochemical pathways initiating inflammation, free radical generation, and apoptosis32. Subcellular localization 
or transfer of Ca2+ from the endoplasmic reticulum (ER) to the mitochondria is important in the control of 
pro-survival/pro-death pathways. We previously reported that when injury-induced influx of Ca2+ is taken up by 
the mitochondria, it initiates apoptosis. Blockade of Ca2+ uptake by the ER and mitochondria via overexpressing 
Bcl-2 results in elevation of intracellular Ca2+ that in turn triggers signaling cascades of CREB (cAMP response 
element-binding protein) and Erk (Extracellular receptor kinase) and elicits neurite outgrowth and axon regen-
eration8. During development, elevated levels of intracellular Ca2+ 8,33 and mTOR phosphorylation22 are distin-
guishing features of neurons which actively extend axons34,35. These dynamics of intracellular Ca2+ level change 
and mTOR activation correlate with the expression of IGFBPL1 in the developing retina, supporting a role for 
Figure 6. Activation of Ca2+ signaling by co-application of IGFBPL1 and IGF-1. (A) Representative 
photomicrographs of cultured RGCs derived from P10 mouse pups immunolabeled with Tuj1 to reveal RGCs 
and axonal processes. Cells were treated with IGF-1, IGFBPL1 or both for 3 days, and cells treated with PBS 
served as vehicle controls. Scale bar: 20 μm. (B,C) Quantification of axon length (B) and percentage of cells 
bearing axons (C) in cultured P10 RGCs. (D) Quantification of RGC survival (n = 5 cultures/group). (E) 
Quantification of axonal growth in cultured P10 RGCs treated by varying doses of IGFBPL1 and/or IGF-1. 
n = 5 cultures/group. **P < 0.01 and ***P < 0.001, as compared to the controls by two-tailed student t-test. 
Error bars indicate standard error of mean (SEM). (F) Changes of [Ca2+]i in cultured P10 RGCs following 
administration of IGFBPL1, IGF-1 or IGFBPL1 + IGF-1. Elevation of [Ca2+]i was induced only when both 
IGFBPL1 and IGF-1 were added. (G) Quantification of [Ca2+]i levels in different treatment groups at 800 s time 
point after stimulation (n = 5 cultures/group, and 10–20 neurons were recorded from each group).
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IGFBPL1 in this regulation. Studies have shown that IGFBPL1 is widely localized in the developing mouse brain 
with a spatiotemporal pattern closely coincides with the time window when neurons are extending axons, but 
restricted to late-born neurons in the postnatal stage36. These observations suggest a conserved mechanism which 
may involve IGFBPL1 in controlling axonal growth in other CNS regions.
The relatively mild impact of gene deletion of IGFBPL1 on RGC axon growth in vivo implicates functional 
redundancy or existence of parallel pathways in the mediation of IGF-1 signaling. To date, at least 7 IGFBPs 
have been identified, and the involvement of these proteins in axon growth have not been well characterized. 
Our screening for other IGFBP members during the period of exuberant RGC axon growth detected dynamic 
expression of other IGFBPs in the developing retina. It remains possible that other IGFBP family members may 
carry out parallel functional roles as IGFBPL1 to mediate the axon growth signaling of IGF-1. Moreover, many 
transcription factors, including p53, SnoN, E47, CREB, STAT3, NFAT, c-Jun, ATF3, Sox4, Sox11, NFκB, PTEN, 
KLFs, etc., have been shown to regulate neurite growth in vitro and in vivo37–39. Screening of these transcription 
factors in Igfbpl1−/− mice suggests that IGFBPL1 critically regulates ATF3 and KLF4 expression in developing 
RGCs (unpublished data). Uncovering the specific subsets of transcription factors underlying the secretory factor 
IGFBPL1 or hormonal control of axon growth is not only of potential therapeutic importance, but would also 
further our understanding for the mechanisms of nerve regeneration. In the future, it would be most interesting 
also to elucidate how IGFBPL1/IGF-1 signaling participates in the regulation of axon development and if other 
IGFBPs play an agonistic or antagonistic role in IGF-1-mediated axon growth activities.
In summary, the present study has revealed a novel secretory factor that participates in the activation of the 
axon growth machinery in developing RGCs through an IGF-1-dependent mechanism. These findings offer new 
perspectives for contemplating axon development regulation and regeneration and provide additional guidance 
in developing new therapeutic approaches to treat optic nerve injury and degeneration.
Materials and Methods
Mice. C57BL/6 J wild-type (Charles River Laboratories) and Igfbpl1−/− mice at a C57BL/6 J genetic back-
ground (Knockout Mouse Project Repository, University of California at Davis) were used in these experiments. 
All mouse studies were approved by the Schepens Eye Research Institute Animal Care and Use Committee and 
performed in accordance with institutional and federal guidelines.
Immunohistochemistry. Retinal sections (10 μm thickness) and retinal whole-mounts were prepared, and 
immunofluorescent labeling was performed as previously described40. Retinal whole-mounts were incubated with 
primary antibody for 24 hours at 4 °C, followed by three washes in 0.01 M Phosphate buffered saline and incu-
bation with secondary antibody for 2 hours at room temperature. Retinal whole-mounts or sections were then 
mounted with VECTORSHIELD mounting medium containing DAPI (Vector Laboratories). Primary antibodies 
against Tuj1 (Millipore, 1:800), IGF-1 (R&D systems, 1:50), and IGFBPL1 (R&D systems, 1:50) were used. As 
Figure 7. Requirement of intracellular Ca2+ elevation for IGFBPL1 and IGF-1-mediated RGC axonal growth. 
(A–C), Representative photomicrographs of RGC cultures (A), survival rate (B) and quantification of axon 
length (C) in cultures treated with PBS or IGFBPL1 + IGF-1 in the absence or presence of Ca2+ chelators 
EGTA or Ca2+ channel blocker Nifedipine. Cells and neuronal processes were visualized with Calcein AM. 
Scale bar: 20 µm. Addition of Ca2+ blockers completely abolished RGC axon outgrowth. (D–F) Representative 
photomicrographs (D), survival rate (E) and quantification of axon length (F) from cultured RGCs treated with 
PBS or IGFBPL1 + IGF-1 in the presence of a potent L-type Ca2+ channel activator FPL64176. Cells and neuronal 
processes were visualized with Calcein AM. Scale bar: 20 µm. *P < 0.05, as compared to vehicle control treated 
group by two-tailed student tests; NS: non-significant. Error bars indicate standard error of mean (SEM).
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antibody specificity or negative controls for IGF-1 and IGFBPL1, the primary antibodies were omitted from 
the staining procedure, and P0 retinal sections (located in the same sections) which stain specifically with the 
primary antibody were used as positive controls. The specimens were visualized and photographed under Leica 
confocal microscope.
For RGC counting, retinal flat-mounts were divided into quadrants using the optic nerve head (ONH) as the 
origin: superior, temporal, nasal and inferior. Within each quadrant, four squares (198 µm × 198 µm) distributed 
at a 1 mm interval along the radius were selected: one from the peripheral region (2 mm from the ONH), two 
from the intermediate region (1 mm from the ONH), and one from the central region. Thus, total 16 square 
regions of each eye were photographed, and all Tuj1+ cells in the ganglion cell layer were counted. Average RGC 
densities of the entire retina were calculated.
Immunocytochemistry was used to determine RGC cell survival, axonal growth, and activation of signaling 
molecules including PI3K and mTOR. Briefly, cultured RGCs in 96-well plate were fixed with 2% paraformal-
dehyde for 15 min followed by immunostaining with primary antibodies against RGC marker Tuj1 (Millipore, 
1:800), Phospho-PI3K (Cell Signaling, 1:50), or Phospho-mTOR (Cell Signaling, 1:50). Corresponding second-
ary antibodies were obtained from Jackson ImmunoResearch Laboratories Inc. Confocal images were acquired 
using a Leica confocal microscope and the LAS AF software. At least 8 images were acquired from each well. The 
longest axon of each cell, the number of cells bearing axons, and the fluorescent intensity of phosphor-PI3K or 
phosphor-mTOR were measured using ImageJ. All assays were repeated at least 4–6 times, and quantifications 
were carried out in a double-blind fashion.
Figure 8. Activation of PI3K and mTOR signals by IGFBPL1 and IGF-1-mediated Ca2+ signaling. (A–D) 
Representative Western blots of triplicate experiments (A,C) and quantification (B,D) of PI3K and mTOR 
phosphorylation following treatment with IGFBPL1, IGF-1, or both in P10 retinal cultures. The levels of 
phosphorylated PI3K (P-PI3K) and phosphorylated mTOR (P-mTOR) increased drastically in cultures 
co-treated with IGFBPL1 and IGF-1 as compared to that was with IGF-1 or IGFBPL1 alone. The western 
blot images were cropped for better overview. The original images are shown in Supplementary Fig. 4. (E) 
Representative photomicrographs of cultured RGCs immunolabeled for phospho-PI3K (P-PI3K) or phospho-
mTOR (P-mTOR) after being treated with IGFBPL1 + IGF-1, IGFBPL1 + IGF-1 + BAPTA or FPL64176. Scale 
bar: 20 um. (F) Quantification of fluorescent intensity of P-PI3K in control and different treatment groups. 
BAPTA inhibited IGFBPL-1 and IGF-1 induced phosphorylation of PI3K, while administration of FPL64176 
alone was sufficient to induce robust PI3K phosphorylation to an extent that was comparable to IGFBPL1 and 
IGF-1 co-treatment. ***P < 0.001, **P < 0.01, *P < 0.05, as indicated by two-tailed student t-test. Error bars 
indicate standard error of mean (SEM).
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Quantitative RT-PCR. RNA was prepared from freshly dissected retinas and cDNA was synthesized 
using the SuperScript® III First-Strand Synthesis System (Life Technologies). Quantitative PCR was performed 
using KAPA SYBR® FAST 2× qPCR Master Mix (Kapa Biosystems) and Eppendorf Mastercycler ep realplex2 
(Eppendorf North America). Primers used in this study: IGFBPL1 Forward 5′ CTGTATGACCCTGGGCAAGT 3′; 
Reverse 5′ GCCAGACCCAATTACGTGTT 3′; GAPDH Forward 5′ AACTTTGGCATTGTGGAAGG 3′; Reverse 
5′ TGTTCCTACCCCCAATGTGT 3′.
Neuron culture preparation and quantification for cell survival and neurite growth. Purification 
of RGCs was performed as previously described41. RGCs (5 × 104 cells/well) were seeded in 96-well culture plates 
that were pre-coated with Poly-D-Lysine (Millipore, 0.1 mg/ml) and merosin (EMD Millipore, 5 μg/ml), and 
maintained in a humidified tissue culture incubator in the presence of 5% CO2 for 3 days. In some experiments, 
the following reagents or chemicals were added into the culture medium immediately after the cells were seeded: 
recombinant mouse IGF-1 (R&D systems), recombinant mouse IGFBPL1 (R&D systems), H-135624,42 (Bachem, 
40 μM), and NBI-3177214 (EMD Millipore, #479830, 10 μM). After 3 days of incubation, cells were washed 
with Dulbecco’s Phosphate-Buffered Saline and stained with CalceinAM and EthD-1 (LIVE/DEAD® Viability/
Cytotoxicity kit, Life Technologies) for 30 min at room temperature. Five images, one from the center and four 
from the periphery, were obtained from each well using an Olympus inverted fluorescence microscope. Live 
and dead cells were counted using ImageJ software, and the rates of cell survival were calculated as Live cells/
(Live + Dead cells)%. To quantify for axonal outgrowth, cells were fixed with 2% paraformaldehyde for 15 min fol-
lowed by immunostaining with primary antibody against RGC marker Tuj1 (1:800) and corresponding secondary 
antibody immunostaining. The longest axon of each cell and number of cells bearing axons were measured using 
ImageJ. All assays were repeated in at least 4–6 independent experiments, and quantifications for cell survival and 
axonal growth were carried out in a masked fashion.
PC12 cells were cultured in RPMI supplemented with 5% FBS, 10% horse serum, and a mixture of 1% of 
penicillin/streptomycin and incubated at 37 °C in a humid 5% CO2 environment. PC12 cells were differentiated 
with 100 ng/ml nerve growth factor for 5 days under different conditions. For hippocampal neuron cultures, 
hippocampi were dissected from P0 mouse pups, dissociated with papain (Worthington Biochemical, LK003150) 
and incubated as described above in a humidified tissue culture incubator with 5% CO2 for 3 days.
Acute knockdown of IGFBPL1 and IGF-1 with lentiviral shRNA. IGFBPL1 shRNA and scrambled shRNA 
(Sigma-Aldrich) were packaged individually into a lentiviral vector (pLKO.1-puro-CMV-TurboGFPTM-igfbpl1 
and pLKO.1-puro-CMV-TurboGFPTM-scrambled shRNA) by DOM Vector Core at the University of California 
at Los Angeles. Transduction was carried out in 96-well culture plates with 0.5 μL of lentivirus stock solution 
(~1 × 108 TU/ml) in each well that were pre-seeded with 5 × 104 primary RGCs for 6 hours. Cells were allowed to 
grow for 3 days before analysis.
Co-IP and Western blots. Co-immunoprecipitation (co-IP) of IGFBPL1 and IGF-1 was performed using 
the Pierce Co-IP kit (Thermo Scientific) following manufacturer’s instruction. Briefly, 50 μl of resin was loaded 
into the Pierce Spin Column and washed twice with 200 μL of 1× Coupling Buffer. IGFBPL1 antibody (16 μg; 
goat anti-IGFBPL1, R&D systems) or IGF-1 antibody (goat anti-IGF-1, R&D systems) was diluted in 200 μL of 
1× Coupling Buffer containing 3 μL of the Sodium Cyanoborohydride Solution and was incubated with resin 
in the spin column for 120 min at room temperature on a mini rotator. The spin column was washed twice with 
200 μl of 1× Coupling Buffer, followed by a wash with quenching buffer, and incubated with 200 μL of quenching 
buffer containing 3 μL of the Sodium Cyanoborohydride Solution for 15 min with gentle shaking. The resin was 
washed with 200 μL of 1× Coupling Buffer twice followed by 6 washes with 150 μl of Wash Solution. Retinal lysate 
from P0 mouse pups was pre-cleared using the control agarose resin. The antibody-coupled resin was washed 
with 200 μl of IP Lysis/Wash Buffer twice, and 200 μl of pre-cleared retinal lysate was added and incubated at 
4 °C overnight. The resin column was washed with 200 μl of IP Lysis/Wash Buffer three times and centrifuged to 
remove the Lysis/Wash Buffer. Captured proteins were eluted by 50 μl of elution buffer and were examined for the 
presence of IGFBPL1 or IGF-1 by Western Blot. Resin was regenerated and stored for future use. Western blot 
was performed as previously described43. In brief, the retinas were homogenized, and 30–50 μg of total protein 
from retina homogenates were run on a 4–20% polyacrylamide gel. Membranes were blocked with 25 mM Tris·Cl 
(pH 7.5) buffer containing 5% non-fat milk, and probed with appropriate primary and secondary antibodies. The 
IRDy®-conjugated secondary antibodies were visualized with the LI-COR Odyssey® system, and the horseradish 
peroxidase (HRP)-conjugated secondary antibodies (Pierce, Rockford, IL). Signals were detected with enhanced 
SuperSignal West Chemiluminescent Substrates on CL-XPosure Film (Thermo Scientific).
Measurement of [Ca2+]i. RGCs were cultured for 48 hours in multi-chamber culture slides pre-coated with 
Poly-D-Lysine and merosine. Cells were loaded with 1 μM Fura-2 and 8 μM pluronic acid F127 in the culture 
medium at 37 °C tissue culture incubator for 30 min. Cells were then washed twice with mammalian Ringer’s solu-
tion and maintained in Ringer’s solution containing 250 μM sulfinpyrazone for calcium imaging. Recombinant 
mouse IGF-1 and IGFBPL1 were dissolved in Ringer’s solution containing 250 μM sulfinpyrazone. Real-time 
imaging of intracellular calcium was acquired using a ratio imaging system InCyt Im2 (Intracellular Imaging, 
Cincinnati, OH) at the excimer wavelengths of 340 and 380 nm and an emission wavelength of 505 nm. Data was 
presented as the actual [Ca2+]i with time.
Treatment of cultures with calcium modulators. RGCs were purified and cultured with the presence or 
absence of IGFBPL1 + IGF-1 and chemicals that modulate intracellular calcium levels for three days. The calcium 
chelators EGTA (0.1 mM) and the calcium channel blocker Nifedipine (25 μM) were used to lower intracellular 
www.nature.com/scientificreports/
1 2ScIEntIfIc RepoRts |  (2018) 8:2054  | DOI:10.1038/s41598-018-20463-5
calcium concentration [Ca2+]i; the L-type calcium channel activator FPL-64176 (0.5 μM) was used to increase 
[Ca2+]i. After three days of treatment, cells were loaded with Calcein AM for axonal growth measurements.
Axon counts in optic nerve cross sections. Mouse optic nerve samples were fixed with half-strength 
Karnovsky’s fixative. Semi-thin optic nerve cross sections (1.0 μm) taken at 2 mm posterior to the globe were 
stained with 2% paraphenylenediamine aqueous solution to stain the axons. Twelve square regions (22.05 µm × 
20.64 µm) distributed at four quadrants, of which 4 were taken from the central region and 8 from the peripheral 
region, were photographed. Using ImageJ, all axons in the photomicrographs were automatically counted and 
the areas of the optic nerve sections were measured. Axonal density was recorded, and the total axon number per 
optic nerve was calculated as (axon density x total area of the nerve cross section). All quantification procedure 
was carried out in a masked fashion.
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